Antidepressant use and breast cancer risk

Chien, Chloe; Li, Christopher I.; Heckbert, Susan R.; Malone, Kathleen E.; Boudreau, Denise M.; Daling, Janet R.

doi:10.1007/s10549-005-9056-0

Cited by 43 publications

(54 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar to our study, most prior studies have found little or no association with ever use of antidepressants (all classes combined) For use of tricyclic antidepressants, no increased risks were seen in most studies for current (Chien et al, 2005;Gonzalez-Perez and Garcia Rodriguez, 2005) or ever use (Kelly et al, 1999;Cotterchio et al, 2000;Wang et al, 2001;Sharpe et al, 2002;Moorman et al, 2003;Steingart et al, 2003;Chien et al, 2005). In the present study, there was a weak positive association when adjusted only for matching factors and this was attenuated when adjusted for additional potential confounders.…”

Section: Discussionsupporting

confidence: 82%

“…Antidepressant use has increased steadily (Stafford et al, 2001;Pirraglia et al, 2003;Meijer et al, 2004) since the introduction of selective serotonin reuptake inhibitors (SSRIs) in the late 1980s, with use reported by 10 -20% of women in recent studies (Moorman et al, 2003;Steingart et al, 2003;Chien et al, 2005), though actual use is likely to be higher due to underreporting (Boudreau et al, 2004).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Use of antidepressant medications in relation to the incidence of breast cancer

et al. 2006

View full text Add to dashboard Cite

Although associations have been reported between antidepressant use and risk of breast cancer, the findings have been inconsistent. We conducted a population-based case -control study among women enrolled in Group Health Cooperative (GHC), a health maintenance organization in Washington State. Women with a first primary breast cancer diagnosed between 1990 and 2001 were identified (N ¼ 2904) and five controls were selected for each case (N ¼ 14396). Information on antidepressant use was ascertained through the GHC pharmacy database and on breast cancer risk factors and screening mammograms from GHC records. Prior to one year before diagnosis of breast cancer, about 20% of cases and controls had used tricyclic antidepressants (adjusted odds ratio ¼ 1.06, 95% CI 0.94 -1.19) and 6% of each group had used selective serotonin reuptake inhibitors (OR ¼ 0.98, 95% CI 0.80 -1.18). There also were no differences between cases and controls with regard to the number of prescriptions filled or the timing of use. Taken as a whole, the results from this and other studies to date do not indicate an altered risk of breast cancer associated with the use of antidepressants overall, by class, or for individual antidepressants.

show abstract

Section: Discussionsupporting

confidence: 82%

mentioning

confidence: 99%

Use of antidepressant medications in relation to the incidence of breast cancer

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Conflicting results of antidepressant use and de novo cancer risk have been reported [264][265][266][267][268][269][270]. A case-control study found no association between antidepressant use and breast cancer risk; a protective effect of paroxetine hydrochloride was observed in subjects who were not overweight [264].…”

Section: Antidepressant Usementioning

confidence: 99%

“…This variation may be attributed to the types of breast cancer. SSRIs increased the risk of PR-and ER+/PR tumors, but not other types of breast cancer [266]. The association between antidepressants and breast cancer are mixed in the preclinical and clinical data.…”

Section: Antidepressant Usementioning

confidence: 99%

“…Studies exist determining if an association exists between antidepressant use and cancer risk [264][265][266][267][268][269][270]283] and antidepressant use and recurrence of cancer [258,272,277,278], but to our knowledge, no studies exist determining if antidepressant use is associated with an increase in brain metastasis in humans. Shapovalov et al found an association between pretreatment with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), and an increase in brain metastasis from breast cancer in mice [14].…”

Section: Antidepressant Usementioning

confidence: 99%

See 1 more Smart Citation

Antidepressant use and risk of central nervous system metastasis

et al. 2016

View full text Add to dashboard Cite

Prolactin and breast cancer: The need to avoid undertreatment of serious psychiatric illnesses in breast cancer patients: A review

Brandao

Strasser‐Weippl

Goss

2015

Cancer

View full text Add to dashboard Cite

Hyperprolactinemia, defined as a sustained elevation of prolactin (PRL) levels greater than 530 mIU/L in women and greater than 424 mIU/L in men, has been implicated for a long time in breast cancer etiology and prognosis. Elevated PRL values (approximately 2-3 times higher than the reference values) are a common adverse effect of antipsychotic medications, especially with firstgeneration drugs, and most antipsychotics carry a standard warning regarding PRL elevations on their US product labels. These associations foster undertreatment of serious psychiatric illnesses in both otherwise healthy patients and cancer patients. This review assesses both the preclinical and clinical evidence that has led to the hypothesis of PRL's role in breast cancer risk or breast cancer progression. It is concluded that taken together, the published data are unconvincing and insufficient to deprive cancer patients in general and breast cancer patients specifically of potentially effective antipsychotic or antidepressant medications for serious psychiatric indications. We thus call on revised medication guidelines to avoid the existing undertreatment of serious psychiatric illnesses among cancer patients based on an unproven contraindication to psychiatric medications. Cancer 2016;122:184-8. V C 2015 American Cancer Society.KEYWORDS: antidepressive agents, antipsychotic agents, breast neoplasms, depression, prolactin. INTRODUCTIONBreast cancer is the second most common cancer worldwide and is the most frequent cancer among women.1 Aside from a few relatively infrequent specific causes such as BRCA1 and BRCA2 mutations, a prior history of radiation therapy in adolescence, and a personal history of pre-invasive lesions, the cause or causes of breast cancer are largely unknown. Since the 1990s, one hypothesis has focused on a causal role for prolactin (PRL) in breast tumorigenesis and prognosis. This review summarizes the preclinical and clinical evidence for a role of PRL in breast cancer etiology and prognosis. Our report also focuses on the possible influence of psychiatric drugs on PRL levels and on their putative indirect influence on the pathogenesis of breast cancer. Finally, our review endeavors to weigh the existing evidence for and against the use of antipsychotic drugs in breast cancer patients.

show abstract

Antidepressant use and breast cancer risk

Abstract: Based on these results and those of previous studies, there is limited evidence that any type of antidepressant use is associated with breast cancer risk overall. SSRIs may elevate risks of PR- and ER+/PR- tumors, though further studies are needed to confirm these associations.

Cited by 43 publications

References 25 publications

Use of antidepressant medications in relation to the incidence of breast cancer

Use of antidepressant medications in relation to the incidence of breast cancer

Antidepressant use and risk of central nervous system metastasis

Prolactin and breast cancer: The need to avoid undertreatment of serious psychiatric illnesses in breast cancer patients: A review

Contact Info

Product

Resources

About